ReviewACS omega2023
Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022.
Ankit Kumar Singh et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this papertrialcites it
ReviewACS omega2023
Ankit Kumar Singh et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.